Convexia
convexia.bioUncover drug assets 10x faster with AI-powered sourcing and evaluation
Health & Wellnessdrug-discoverybiotechai-agentspharmaceuticalin-silicodrug-sourcinglife-sciences
About
Convexia is an AI-driven drug sourcing and evaluation platform that helps pharma, biotech, and investment groups discover overlooked drug assets globally. It combines specialized AI agents for in silico simulation, market analysis, and operational risk scoring with human expert review at each stage. The platform is also licensing individual modules and running pilots, with a long-term goal of acquiring and developing drug assets independently.
Problem
Traditional drug scouting misses high-potential overlooked assets and lacks rigorous, scalable AI-assisted evaluation and risk scoring.
For
pharma companies, biotech firms, and investment groups seeking drug asset discovery and diligence
How it works
Convexia uses a multi-step pipeline of specialized AI agents — covering asset discovery, in silico evaluation, market analysis, and operational risk scoring — combined with PhD-level human review and KOL roundtables to produce go/no-go decisions on drug assets.
Business model
subscription
Status
launched
Company
Convexia